tiprankstipranks
Trending News
More News >
Relmada Therapeutics (RLMD)
NASDAQ:RLMD
US Market
Advertisement

Relmada Therapeutics (RLMD) Income Statement

Compare
352 Followers

Relmada Therapeutics Income Statement

Last quarter (Q1 2025), Relmada Therapeutics's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q1, Relmada Therapeutics's net income was $-17.56M. See Relmada Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit
$ 0.00$ 0.00$ 0.00$ -1.26K$ -3.75K
Operating Expenses
$ 30.18M$ 103.70M$ 161.25M$ 125.70M$ 60.84M
Depreciation and Amortization
$ 83.89M$ 103.70M$ 2.00K$ 1.26K$ 3.75K
EBITDA
$ -79.98M$ 4.91M$ -157.04M$ -125.75M$ -59.45M
Operating Income
$ -83.89M$ -103.70M$ -161.25M$ -125.70M$ -60.84M
Other Income/Expenses
$ 3.91M$ 4.91M$ 4.21M$ -48.32K$ 1.38M
Pretax Income
$ -79.98M$ -98.79M$ -157.04M$ -125.75M$ -59.46M
Net Income
$ -79.98M$ -98.79M$ -157.04M$ -125.75M$ -59.46M
Per Share Metrics
Basic EPS
$ -2.65$ -3.28$ -5.30$ -7.16$ -3.81
Diluted EPS
$ -2.65$ -3.28$ -5.30$ -7.16$ -3.81
Weighted Average Shares Outstanding
30.16M 30.10M 29.63M 17.55M 15.59M
Weighted Average Shares Outstanding (Diluted)
30.16M 30.10M 29.63M 17.55M 15.59M
Currency in USD

Relmada Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis